FDA kicks off review of second kidney cancer combo based on BMS’ OpdivoBristol-Myers Squibb could be mere months away from claiming a second US approval for an Opdivo-based combination immunotherapy Share XFDA kicks off review of second kidney cancer combo based on BMS’ Opdivohttps://pharmaphorum.com/news/fda-starts-review-of-second-kidney-cancer-use-for-bms-opdivo/
Scotland backs two myeloma drugs turned down by NICE in EnglandA north-south divide threatens to emerge in multiple myeloma in the UK, after the Scottish Medicines Consortium (SMC) Share XScotland backs two myeloma drugs turned down by NICE in Englandhttps://pharmaphorum.com/news/scotland-backs-two-myeloma-drugs-tuned-down-by-nice-in-england/
Data sets up ulcerative colitis expansion for BMS’ MS drug ZeposiaBristol-Myers Squibb’s Zeposia (ozanimod) is already tipped for blockbuster sales in its first indication – multiple sclerosis – Share XData sets up ulcerative colitis expansion for BMS’ MS drug Zeposiahttps://pharmaphorum.com/news/data-sets-up-ulcerative-colitis-expansion-for-bms-ms-drug-zeposia/
BMS bulks up in cardio with $13.1bn takeover deal for MyoKardiaBristol-Myers Squibb has said it will buy biotech MyoKardia in a $13.1 billion takeover that marks a step Share XBMS bulks up in cardio with $13.1bn takeover deal for MyoKardiahttps://pharmaphorum.com/news/bms-bulks-up-in-cardio-with-13-1bn-takeover-deal-for-myokardia/
FDA approves BMS’ Opdivo and Yervoy combination in first-line mesotheliomaBristol-Myers Squibb’s immunotherapy combination of Opdivo and Yervoy has been approved in the US in a new indication Share XFDA approves BMS’ Opdivo and Yervoy combination in first-line mesotheliomahttps://pharmaphorum.com/news/fda-approves-bms-opdivo-and-yervoy-combination-in-first-line-mesothelioma/
FDA’s review date for BMS’ ide-cel sneaks under the CVR wireThe FDA has given a 27 March 2021 review date for Bristol-Myers Squibb’s multiple myeloma cell therapy ide-cel, Share XFDA’s review date for BMS’ ide-cel sneaks under the CVR wirehttps://pharmaphorum.com/news/fdas-review-date-for-bms-ide-cel-sneaks-under-the-cvr-wire/
BMS swoops on Forbius, snaring another immuno-oncology playerWith the ink barely dry on a deal to develop Dragonfly’s lead cancer immunotherapy, Bristol-Myers Squibb’s business development Share XBMS swoops on Forbius, snaring another immuno-oncology playerhttps://pharmaphorum.com/news/bms-swoops-on-forbius-snaring-another-immuno-oncology-player/
BMS signs $475m cancer immunotherapy deal with DragonflyBristol-Myers Squibb has signed an agreement worth $475 million to develop a new form of cancer immunotherapy drug Share XBMS signs $475m cancer immunotherapy deal with Dragonflyhttps://pharmaphorum.com/news/bms-signs-475m-deal-to-develop-cancer-immunotherapy-with-dragonfly/
FDA to decide on TG Therapeutics’ lymphoma drug early next yearThe FDA has accepted TG Therapeutics’ filing for its lymphoma drug umbralisib, which if approved could compete against Share XFDA to decide on TG Therapeutics’ lymphoma drug early next yearhttps://pharmaphorum.com/news/fda-to-decide-on-tg-therapeutics-lymphoma-drug-early-next-year/
